<a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products?category=136&amp;manufacturerItems=50&amp;page=2">Solid phase extraction</a> is routinely selected as a sample preparation technique prior to HPLC and GC analysis. It provides:<ul><li>Clean-up;</li><li>Analyte pre-concentration;</li><li>Solvent switching.</li></ul>This works well for any homogeneous liquid samples, but clearly a solid sample cannot be applied directly to an SPE device. Here we will consider how best to approach the handling of solid samples prior to SPE.The first stage of sample pre-treatment involves homogenising the solid sample with a suitable solvent. The solvent selected for this purpose will:<ul><li>Be effective at solubilising the analyte.</li><li>Be effective at solubilising the sample matrix, although this is not necessary providing the sample is blended well with the solvent.</li><li>Ideally it will be a weak solvent when it comes to the SPE stage. This may not be possible, and it may be necessary to dry down and reconstitute the sample prior to loading on to the SPE cartridge.</li></ul>Having formed a suspension of the sample in a suitable solvent the sample should be vortexed to promote thorough mixing, and then centrifuged to pellet the insoluble components of the matrix. The solvent should then be removed for further treatment.At this point the SPE mechanism needs to be selected:&nbsp;<h3>Reversed Phase SPE Method</h3>Mechanism / Weak Solvent / Strong Solvent<ul><li>Reversed phase – Water/buffer – Acetonitrile/Methanol (hexane strongest)</li><li>Normal phase – Hexane/Heptane – Mid polar organic such as DCM, MTBE, IPA (strongest is water)</li><li>Ion exchange – Aqueous buffer at a pH which promotes ion exchange interactions between analyte and SPE sorbent – Organic solvent, typically methanol with pH adjustment to disrupt the ion exchange interactions.</li></ul>Analyte properties and sample diluent both need to be considered at this point. Reversed phase extractions are effective for moderately polar to moderately hydrophobic analytes, but only if they are dissolved in a weak solvent such as water. If the sample is dissolved in a mid-polar solvent the sample will either need to be diluted, or alternatively dried down and reconstituted. The same is true for normal phase, where samples need to be dissolved in hexane/heptane for analytes to be successfully retained during sample loading onto the SPE device.These examples will hopefully illustrate this concept.<h4>The extraction of PCBs from soil.</h4>PCBs are hydrophobic and will dissolve readily in a non-polar solvent. Soil can be dried, weighed and then extracted using hexane (or heptane). Once thoroughly mixed and centrifuged the resulting solution can be applied directed to a conditioned silica SPE tube allowing for a normal phase extraction to be conducted.<h4>Tylosin from meat.</h4>Tylosin is an antibiotic, with a log P of 1.0. Extracting from meat with a mixture of acetonitrile and water (80:20) will break any hydrophobic interactions releasing the tylosin. After centrifugation the resulting liquid sample will require further dilution with water to reduce the loading solvent strength prior to a reversed phase extraction.<h4>Enilconazole from oranges.</h4>Enilconazole is a fungicide widely used in agriculture and is often used with citrus fruits. It can readily be extracted from oranges using acetonitrile. As enilconazole is basic, the addition of HCl to the acetonitrile extract will promote protonation of the analyte, allowing for it to be directly retained on a strong cation exchange SPE material. This greatly simplifies the extraction process as no dilution of the sample is required (in contrast to reversed phase, or normal phase extraction where 100% acetonitrile would cause the analyte to be unretained during loading).

Considerations when working with solid samples and SPE

ALS recognizes that Climate Change is one of the defining issues of our time and we strive to make Impact through Action in the areas of Sustainability, linked to the ALS core value of Caring.ALS intends to make the world a better place through innovation, science, and commitment to best practice. This year the ALS Board has signed off on a company commitment to Net Zero by 2050 as summarized on our <a target="_blank" rel="noopener noreferrer" href="https://www.alsglobal.com/en/sustainability?utm_source=email-sig-link-ca&amp;utm_medium=email&amp;utm_campaign=sustainability-report-23">annual sustainability report</a>. ALS is pleased to share our milestones and targets with clients.<h3>Background</h3>In 2021, ALS developed a climate change strategy, setting a target of 40% reduction in scope 1 &amp; 2 emissions by 2030. By end of FY23 (March 2023), ALS had achieved a 58% reduction, and achieved carbon neutrality for scope 1 &amp; 2 emissions – well ahead of plan. In the same month, ALS recorded a key milestone with the ALS Board approving our roadmap to reach Net Zero by 2050 (shared at right), with milestones noted and completed actions shaded green.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/ALS_Czech_Republic_Enviro_Mail_12_Europe_ALS_Net_Zero_Commitments_and_Roadmap_in_Support_of_our_Staff_Clients_Communities_and_Shareholders_b157904cab.jpg" alt="ALS Czech Republic: EnviroMail™12/Europe: ALS Net Zero Commitments &amp; Roadmap in Support of our Staff, Clients, Communities &amp; Shareholders." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_ALS_Czech_Republic_Enviro_Mail_12_Europe_ALS_Net_Zero_Commitments_and_Roadmap_in_Support_of_our_Staff_Clients_Communities_and_Shareholders_b157904cab.jpg 112w," sizes="100vw" width="805" height="1120"><h3>Further detail</h3>Key projects to date have included purchasing Renewable Electricity (RE) from the grid (we utilize greater than 90% RE across all operations), installing &gt;1.8MW of solar photovoltaic (PV) systems across 16 site locations, and continued implementation of our ALS Green Building Standards, which focus on HVAC systems, building insulation, LED lights, energy efficient plant and equipment, moving to electric vehicles (EVs), and staff engagement on adopting climate friendly practices to reduce actual energy demand.This ALS Net Zero commitment will involve reducing absolute scope 1 and 2 emissions by 95% and scope 3 emissions by 90% by 2050, against a 2020 baseline year. This is a challenging task for laboratory operations given requirements for chemical, plastic, and glassware usage, and significant air heating and cooling requirements due to fume hoods which cause frequent cycling of laboratory air.The ALS Roadmap includes a near-term target to reduce absolute scope 1 and 2 greenhouse gas emissions by 78% by 2030 against a 2020 baseline year.Over the next 2 years ALS will measure our scope 3 greenhouse gas inventory to confirm the calculated scope 3 estimate completed in FY2023 and will develop action plans for freight, purchased goods/services, wastes, and employee commutes. A near-term target for 2030 for scope 3 will then be set.Priority actions over the next 5 years will include:<ul><li>purchasing renewable electricity for &gt;95% of our operations</li><li>installing further solar energy PV systems (7 more installed YTD for FY24 with a further 9 systems to be completed in early FY25)</li><li>converting gas ovens and furnaces to electric where possible</li><li>selection of more energy-efficient vehicles; 30% of fleet to be hybrids and EVs by 2030</li><li>upgrading to ALS green building guidelines for new laboratory developments and refurbishments (better insulation, more efficient HVAC, solar PV systems, and upgraded building management systems)</li></ul><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/ALS_Czech_Republic_Enviro_Mail_12_Europe_ALS_Net_Zero_Commitments_and_Roadmap_in_Support_of_our_Staff_Clients_Communities_and_Shareholders_2_91b5e7ebf8.jpg" alt="ALS Czech Republic: EnviroMail™12/Europe: ALS Net Zero Commitments &amp; Roadmap in Support of our Staff, Clients, Communities &amp; Shareholders." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_ALS_Czech_Republic_Enviro_Mail_12_Europe_ALS_Net_Zero_Commitments_and_Roadmap_in_Support_of_our_Staff_Clients_Communities_and_Shareholders_2_91b5e7ebf8.jpg 156w," sizes="100vw" width="1089" height="1089"><blockquote>We are pleased to share our commitments with our stakeholders. Please feel free to contact your local ALS representative for further information.</blockquote>

EnviroMail™12/Europe: ALS Net Zero Commitments & Roadmap in Support of our Staff, Clients, Communities & Shareholders

Solid-phase extraction (SPE) is one of the key techniques in modern analytical chemistry for pre-concentrating analytes prior to chromatographic analysis. However, traditional manual SPE procedures are often time-consuming, error-prone, and difficult to reproduce. In response to laboratories’ increasing demand for automation and efficiency, <a target="_blank" rel="noopener noreferrer" href="https://watrex.com/?utm_source=labrulez&amp;utm_medium=propagace&amp;utm_campaign=labrulez_clanky">Watrex Praha</a> introduces the <a target="_blank" rel="noopener noreferrer" href="https://watrex.com/obchod/laboratory-automation/streamline-ole-200/?utm_source=labrulez&amp;utm_medium=propagace&amp;utm_campaign=labrulez_clanky">Streamline OLE 200</a> – an advanced system for online SPE.&nbsp;<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Watrex_Ole_uvod_oprava_bd77e4d8c2.jpg" alt="Watrex: Streamline™ OLE 200" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Watrex_Ole_uvod_oprava_bd77e4d8c2.jpg 245w," sizes="100vw" width="1599" height="900"><h4>Comprehensive Automation of SPE&nbsp;</h4>The <a target="_blank" rel="noopener noreferrer" href="https://watrex.com/obchod/laboratory-automation/streamline-ole-200/?utm_source=labrulez&amp;utm_medium=propagace&amp;utm_campaign=labrulez_clanky">Streamline OLE 200</a> is a fully automated solid-phase extraction unit designed for direct integration into HPLC systems. It enables efficient pre-concentration of up to eight different samples, minimizes the need for manual handling, and significantly boosts laboratory productivity.<h4>Advantages of SPE Automation with OLE 200&nbsp;</h4><ul><li>Increased laboratory throughput: Automatic processing of up to 8 samples without the need for operator intervention.&nbsp;</li><li>Reduced manual errors and improved result reproducibility.&nbsp;</li><li>Flexible integration: Compatible with any HPLC system, allowing implementation across various laboratory settings.&nbsp;</li><li>Time savings: Eliminates the need to manually transfer samples between the SPE and HPLC steps.&nbsp;</li><li>Multimodal selection of SPE cartridges based on analytes and matrix complexity.&nbsp;</li></ul><h4>Technical Specifications and System Design&nbsp;</h4>At the heart of the system is a high-pressure pump, ensuring precise dosing of both samples and solvents. The system’s design features three key valves:&nbsp;<ul><li>A 10-port selection valve for sample and wash solvent selection.&nbsp;</li><li>A high-pressure SPE cartridge selector, allowing switching between up to five different SPE cartridges.&nbsp;</li><li>A standard injection valve, connecting the device to any HPLC system.</li></ul>This setup ensures that each sample is precisely processed: drawn into an SPE cartridge, washed with one or two eluents, and then eluted directly into the chromatograph.&nbsp;<h4>Functional Diagram&nbsp;</h4><ol><li>The sample is drawn by the pump through the 10-port valve to the selected SPE cartridge.&nbsp;</li><li>The cartridge is washed with one or two eluents to remove interferences.&nbsp;</li><li>Analytes are then eluted with a selected solvent and delivered directly into the HPLC system via the injection valve.&nbsp;</li></ol><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Watrex_OLE_clanek_obr_2_36588f90b9.jpg" alt="Watrex: Fig. 2 - Streamline™ OLE 200 Schematic" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Watrex_OLE_clanek_obr_2_36588f90b9.jpg 245w," sizes="100vw" width="1700" height="957"><h4>Efficiency, Reproducibility, and Flexibility&nbsp;</h4>Automation of the entire SPE process leads to greater reproducibility and reduces the risk of contamination or human error. The system allows sequential processing of multiple samples, each of which can be analyzed following a specific protocol. Thanks to its open design, the OLE 200 is compatible with any HPLC system, making it easy to integrate into existing lab workflows without major modifications.&nbsp;<h4>Application Potential&nbsp;</h4>The OLE 200 system is particularly suitable for:&nbsp;<ul><li>Pesticide and pharmaceutical residue analysis in water&nbsp;</li><li>Clinical and pharmaceutical analysis of biological fluids&nbsp;</li><li>Food safety and environmental monitoring&nbsp;</li><li>Forensic and toxicological analyses&nbsp;</li></ul>Thanks to its modular design and the ability to select various SPE cartridges based on polarity and interactions, the device can be easily adapted to specific applications.&nbsp;<h4>Operation and Software&nbsp;</h4>The system's user-friendly interface enables easy setup of each SPE step, including cartridge selection, volumes, elution solvents, and wash sequences. The entire process can be fully programmed, minimizing the need for operator involvement during analysis.&nbsp;<h4>Conclusion&nbsp;</h4>The <a target="_blank" rel="noopener noreferrer" href="https://watrex.com/obchod/laboratory-automation/streamline-ole-200/?utm_source=labrulez&amp;utm_medium=propagace&amp;utm_campaign=labrulez_clanky">Streamline OLE 200</a> from <a target="_blank" rel="noopener noreferrer" href="https://watrex.com/?utm_source=labrulez&amp;utm_medium=propagace&amp;utm_campaign=labrulez_clanky">Watrex Praha</a> prepresents a modern and powerful tool for automated sample pre-concentration that significantly enhances efficiency, reliability, and accuracy in analytical laboratories. Its flexibility, robust design, and easy integration with existing systems make it an ideal solution for demanding applications in environmental analysis, pharmaceutical research, and routine quality control.&nbsp;<blockquote>Want to learn more? Visit our website at <a target="_blank" rel="noopener noreferrer" href="https://watrex.com/?utm_source=linkedin&amp;utm_medium=propagace&amp;utm_campaign=linkedin_clanky">www.watrex.com</a> or email us at watrex@watrex.com.</blockquote>

Flawless and Effortless: How the Streamline™ OLE 200 Transforms Sample Preparation for HPLC? 

Article

Product

Academy

Video

Environment

For more than 40 years, ALS has provided testing and technical solutions to clients all over the world in a wide range of industries. We have built our global reputation by embracing the latest technologies and innovative methodologies to deliver high quality testing services to clients. ALS is able to leverage a multifaceted international team while remaining agile enough to provide local expertise and personalized solutions to every one of our clients.

ALS Czech Republic

Phenomenex is a global technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers in industrial, government and academic laboratories.

Phenomenex

WATREX Prague is the distributor and producer of HPLC techniques in the Czech Republic and Slovakia. Main Chromatografic and Related Techniques Supported: LC, GPC, IC, IEC, Automated SPE, LC Columns and special column packings, LC method development, Software development, Laboratory Robots.

Watrex Praha

Agilent Technologies

Bruker

Thermo Fisher Scientific

C&EN

Waters Corporation

Novel synthetic drug modalities, like macrocyclic peptides, GLP-1 receptor agonist and proteolysis targeting chimeras (PROTACs®) are rapidly emerging as novel drug modalities for challenging therapeutic targets. Although synthetic in nature, these modalities fall outside Lipinski’s rule of five, thus posing additional ADME challenges, requiring novel approaches for successful lead optimization programs. Recent advancement in Liquid Chromatography High Resolution Mass Spectrometry (LC-HRMS) technology have proven successful in increasing throughput for DMPK assays, as well as confidently identifying metabolic soft spots.This webinar will showcase a novel approach developed by Merck &amp; Co. on using the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer to increased throughput of combined stability testing and metabolite identification, enabling sample multiplexing to speed up the development of macrocyclic peptide drugs. Additionally, the benefit of intelligently acquired MSn fragmentation on the Thermo Scientific™ Orbitrap™ Ascend BioPharma Tribrid™ mass spectrometer for confident PROTACs® metabolite soft spot identification edition will be presented.<h5>Key Learning Objectives:</h5><ul><li>Recent advancement in liquid chromatography mass spectrometry to address DMPK challenges for compounds beyond Lipinski’s “rule of five”</li><li>Strategies to increase throughput in the development of macrocyclic peptide drugs DMPK assays</li><li>Benefits of multi-stage fragmentation techniques for confident PROTAC® metabolic soft spot identification</li></ul><h5>Who Should Attend:</h5><ul><li>DMPK scientists working on peptide/cyclic peptide, PROTACs® and undruggable targets</li><li>Researchers interested in strategies to improve ADME/DMPK properties of cyclic peptides and PROTACs®</li><li>DMPK scientist interested novel LC-MS approach to speed DMPK assays</li></ul><blockquote>Presenter: Congliang Sun, Ph.D. (Sr. Scientist, Merck &amp; Co.)Presenter: Sven Hackbusch, Ph.D. (Senior Applications Scientist, Thermo Fisher Scientific)Presenter: Melissa O'Meara (Forensic Science Consultant, C&amp;EN Media Group)</blockquote>

Thermo Fisher Scientific: Advancement in LC-MS to address DMPK challenges for novel modalities

Advancement in LC-MS to address DMPK challenges for novel modalities

We will showcase a novel approach developed by Merck & Co. on using the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer to increased throughput

Advancement in LC-MS to address DMPK challenges

<div><div>Let's go back to the Basics of Chromatography, Mass Spectrometry, Data Analysis and Trouble-shooting: understanding the importance of the basics will enable you to be more effective in your daily laboratory life.This journey started in 2024 and we are now pleased to invite you to join us to go deeper in fundamentals, troubleshooting and application specific topics.<h3>EPISODE 6: A question of Perspective - Nitrosamines Analysis</h3>What will you learn?<ul><li>Simple workflows to quantify N-Nitrosamines</li><li>Apply the latest regulations for Pharmaceuticals</li><li>A new perspective – with analyses in Food</li></ul>What's next?<ul><li>Check out the full Webinar Series Episodes List <a target="_blank" rel="noopener noreferrer" href="https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;eventid=4817889&amp;sessionid=1&amp;key=B9182AE813B3F8A30217606156F96B75&amp;groupId=5901784&amp;sourcepage=register">here</a></li></ul>Not sure to be able to attend live sessions?&nbsp;<ul><li>Register today and watch the webinars on-demand</li></ul><blockquote>Presenter: Antonia Wierzbicki (Principal MS Market Dev Manager, EMEA, Waters Corporation)Antonia Wierzbicki is a MS market development manager at Waters working in EMEA. Antonia has BSc in Pharmaceutical Science and a MSc in Cancer Pharmacology. Following several years working as an analytical chemist in drug development roles within both academic labs and contract research organizations, Antonia has more recently spent time working with analytical chemists to provide solutions using cutting edge technologies to meet their needs and requirements, with a specific interest in ultra-sensitive quantitation of small molecules. Antonia is based in Cambridge UK and keen to connectwith like-minded scientists in the field.Presenter: Caroline Davis (Senior Sales Application Chemist, Waters)Caroline is part of the Customer Success team at Waters with a focus on LC-MS/MS application and sales support. She works in this role for more than 5 years. Caroline has a strong background in environmental science. She finished her PhD in Environmental Chemistry at ETH Zurich / EAWAG after getting a Bachelor in Chemistry at San Diego State University, US, and a Master in Structural Chemistry and Spectroscopy at Universität Leipzig, Germany.</blockquote></div></div>

Waters Corporation: Back to Basics Advanced Webinar Series 2025

Back to Basics Advanced - Contaminants: Nitrosamines

Simple workflows to quantify N-Nitrosamines. Apply the latest regulations for Pharmaceuticals. A new perspective – with analyses in Food.

<div><div>Let's go back to the Basics of Chromatography, Mass Spectrometry, Data Analysis and Trouble-shooting: understanding the importance of the basics will enable you to be more effective in your daily laboratory life.This journey started in 2024 and we are now pleased to invite you to join us to go deeper in fundamentals, troubleshooting and application specific topics.<h3>EPISODE 7: Importance of PFAS Analyses Prepare For All inSights</h3>What will you learn?<ul><li>Overview on Sample Prep Methods</li><li>Absolute Sensitivity for the know PFAS</li><li>Approaches to find the unknown PFAS</li></ul>What's next?<ul><li>Check out the full Webinar Series Episodes List <a target="_blank" rel="noopener noreferrer" href="https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;eventid=4817889&amp;sessionid=1&amp;key=B9182AE813B3F8A30217606156F96B75&amp;groupId=5901784&amp;sourcepage=register">here</a></li></ul>Not sure to be able to attend live sessions?&nbsp;<ul><li>Register today and watch the webinars on-demand</li></ul><blockquote>Presenter: Kari Organtini, PhD (Principal Scientist, Waters Corporation)Kari Organtini is a principal scientist at Waters Corporation and has been with the company for eight years. She received her PhD from Penn State University in 2015 studying the occurrence of dioxins and furans in fire debris and their implications to first responder health. At Waters, Kari is part of the PFAS Program in the Testing and Lab Services Group. Kari has developed applications using both LC and GC techniques for a variety of applications ranging from pesticides to persistent organic pollutants during her career. She is currently the scientific lead for developing PFAS applications at Waters.Presenter:&nbsp;Mike McCullagh PhD (Principal Consulting Scientist, MS Discovery Program, Waters Corporation)Mike joined Waters Corporation in 2001 and has performed a variety of roles at the company in science, applications and marketing areas. With a strong background in time-of-flight mass spectrometry and ion mobility Mike has experience in several application areas, including; impurity profiling, natural product profiling, authentication profiling and pesticide/veterinary residue screening. With his experience in instrumentation, applications and extensive customer collaborations Mike has a deep understanding of customer challenges and develops new applications strategies and supports instrument development to ensure customers success.</blockquote></div></div>

Back to Basics Advanced - Contaminants: PFAS

Overview on Sample Prep Methods. Absolute Sensitivity for the know PFAS. Approaches to find the unknown PFAS.

Analytical Strategies for mRNA Therapeutics and Vaccines Messenger RNA (mRNA) therapeutics and vaccines represent a groundbreaking advancement in modern medicine.Ensuring their quality, safety, and efficacy requires rigorous analytical methods focused on Critical Quality Attributes (CQAs) such as:<ul><li>mRNA integrity</li><li>Purity</li><li>Capping efficiency</li><li>Residual impurities</li></ul>To characterize and quantify these CQAs, chromatographic techniques play a central role, including:<ul><li>Ion-pair reverse-phase HPLC (IP-RP-HPLC)</li><li>Size-exclusion chromatography (SEC)</li><li>Ion-exchange chromatography (IEX)</li><li>MS Technology &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</li></ul>Sarita and Catalin explore the importance of defining and monitoring critical quality attributes (CQAs) and outline analytical strategies for mRNA characterization and impurity profiling. Sarita emphasizes the value of reference materials in method development, bridging, and assay performance monitoring to ensure process consistency and reliability. Catalin will exemplify the use of mass spectrometry to iterate it's ability to create critical quality attributes.<h5>Key learning objectives:</h5><ul><li>Gain an overall understanding of Critical Quality Attributes for messenger RNA</li><li>Discover the current analytical strategies for creating critical quality attributes. for mRNA thru chromatography and Mass Spectrometry.</li></ul><h5>Who should attend:&nbsp;</h5><ul><li>Analytical Scientist and chemists involved in Method Development, Validation, and Quality Control of mRNA products. &nbsp; Biopharmaceutical and Biotechnology Professionals. &nbsp;Regulatory Affairs Specialists. &nbsp;Process Development Scientists.</li></ul><blockquote>Presenter: Sarita Kattel, M.S. (Principal Scientist, Global Biologics, US Pharmacopeia)Sarita Kattel serves as a Principal Scientist in USP’s Global Biologics Department. At USP, she utilizes her extensive vaccine experience to advance the development of standards supporting vaccine manufacturing. Her role also includes creating new standards for analytical testing of oligonucleotide products and exploring additional opportunities for standards in various other areas.Ms. Kattel’s career spans over biotech companies, academic institutions, contract research organizations (CROs), and pharmaceutical giants like GlaxoSmithKline (GSK) and Janssen Pharmaceuticals. She has held lab-based roles in method development and validation, Chemistry, Manufacturing, and Controls (CMC) leads, as well as quality control, working on monoclonal antibodies, proteins, and mRNA-based vaccines.Presenter:&nbsp;Catalin Doneanu PhD. (Principal Scientist, Waters Corporation)Catalin Doneanu received his Ph.D. in analytical chemistry from Oregon State University in 2002. After a postdoctoral stage in the Department of Medicinal Chemistry at University of Washington in Seattle, he joined Waters Corporation in 2006. He is currently a principal scientist in the Biopharmaceutical Sciences group. He has more than twenty years of experience in separation sciences and mass spectrometry. His current research interests are in the area of therapeutic oligonucleotides and protein characterization using LC-MS. Catalin has over 30 peer-reviewed publications.Moderated by: Samuel Seal (Biopharma Market Development Manager, Waters Corporation)Samuel Seal is a market development manager specializing in the biologics space. He loves LC and MS – especially on how this technology provides benefit and value.Sam joined Waters in January of 2014 as a Sales Technical Support Specialist in the Irvine office/lab. As a TSS he performed demonstrations on various instruments, provided training for customers, often presented on technical information at varying events, and assisted with troubleshooting from Colorado to Los Angeles.He previously worked at Pyxant Labs in Colorado Springs, CO where he gained extensive experience developing and validating methods for small/large molecules in bioanalytical assays, agricultural commodities, registration of pesticides, and worker exposure studies. He also has experience in column chromatography, sample extraction, sample clean-up, reporting and data management. Sam has hands on experience with running and maintaining various manufacturers' LC/MS/MS systems. Prior to Pyxant, Sam was a Laboratory Instructor at the University of Colorado at Colorado Springs where he earned his Bachelor of Arts in Biology and Bachelor of Arts in Chemistry.</blockquote>

Waters Corporation: Solving Problems That Matter - a Waters webinar series featuring USP speakers

mRNA Vaccines

Discover current analytical strategies for creating critical quality attributes for mRNA thru chromatography and MS.

The use of extremely corrosive buffer salts in conjunction with extremely shallow gradients for the best separation makes Biochromatography a challenging application for applied liquid chromatography systems. Successful chromatography necessitates an iron-free flow channel, consistent gradient formation, and the capability to utilize either binary or quaternary pumping systems.Discover how to make changes to the LC system to increase its biocompatibility. Discussion will include biocompatible flow channel for molecules that are prone to metal-induced artifacts. Additionally, we will discuss strategies for lowering PFAS backgrounds from LC instruments. In particular, PFC-free LC conversion kits and associated substitutes for all crucial LC system components made of materials containing organic fluorine compounds will be covered.<blockquote>Presenter: Mohit Patel (Application Engineer, Agilent Technologies, Inc.)Mohit Patel is part of the CSD Online AE Team. His primary focus is to support SMLC, Bio-Columns, and consumables.Before joining Agilent, Mohit was an Assistant Professor of Chemistry at Temple University. Mohit developed his passion for science through his experiences as a faculty researcher and a mentor. Mohit actively taught, developed curriculum, and served as senior personnel, with a leadership position, on funded grants, mentored research projects, and co-coordinator of STEAM related outreach services. Mohit has earned a Doctorate degree in Chemistry from Temple University in 2016.</blockquote>

Agilent Technologies: Becoming a Better Chromatographer - Educational Webinar Series

Benefits of Customizing LC systems for Bioanalysis and PFAS Analysis

Discover how to make changes to the LC system to increase its biocompatibility.

Customizing LC systems for Bioanalysis and PFAS Analysis

<div><div container-id="cq-colctrl-lt0" comp-id="A1"><div>Mass spectrometry (MS) users need software solutions that make it easier to work with complex data while ensuring accurate peak integration and quantitation. Often this comes with limitations around data management, access, and compliance. The new Thermo Scientific™ Chromeleon™ 7.4 software solves these challenges. It will take targeted MS quantitation to the next level, controlled and accessed from anywhere, with native control for Thermo Scientific MS instruments. It provides MSn data support for wide range of applications, network scalability and resilience, and adherence to the most stringent regulatory requirements, all with a single software solution.Join our webinar to learn how Chromeleon 7.4 software provides MS labs with advanced tools for their targeted quantitation workflows by combining the powerful network and compliance capabilities of Chromeleon software with industry-leading Thermo Scientific MS instrumentation to deliver a best-in-class solution.Key Learning Points:<ul><li>How to streamline targeted MS quantitation workflows with Chromeleon 7.4 software</li><li>Ways to manage complex MS data securely, reducing training and administration effort</li><li>How to work remotely with secure access to MS data and instruments from anywhere</li></ul>Who should attend:<ul><li>Mass spectrometry users in environmental, food safety, and (bio)pharma labs</li><li>Lab managers and analysts focused on productivity and data compliance</li><li>Current Chromeleon software users looking to maximize targeted MS quantitation capabilities</li></ul><blockquote>Presenter: Richard Law (Product Manager, Thermo Fisher Scientific)With a background in analytical chemistry and mass spectrometry, Richard is the Product Manager for targeted MS using Chromeleon CDS. He has extensive experience developing applications using LC and GC–MS technologies, especially GC-triple quadrupole MS/MS and HRAM, and has worked across several industry segments.Presenter:&nbsp;Anthony Crawshaw (Product Manager, Thermo Fisher Scientific)With a background in applied chemistry, Anthony brings over 25 years of experience in pharmaceutical analysis and laboratory software. Since 2011, he's helped customers deploying Chromeleon enterprise systems, focusing on streamlining lab operations and ensuring smooth software deployments. Anthony is now the Product Manager for Chromeleon Enterprise software.Presenter:&nbsp;Laércio Fernandes (Product Marketing Manager, Thermo Fisher Scientific)</blockquote></div></div></div>

Thermo Fisher Scientific: Targeted MS quantitation - Controlled and accessed from anywhere

Targeted MS quantitation - Controlled and accessed from anywhere

Join webinar to learn how Chromeleon 7.4 software provides MS labs with advanced tools for their targeted quantitation workflows.

Targeted MS quantitation with Chromeleon 7.4 software

<h4>More information coming soon, stay tuned!</h4><blockquote>Presenter: Phil Borman, Ph.D. (Sr Director, Pharma R&amp;D, GSK)Dr. Phil J. Borman is a fellow of the Royal Society of Chemistry with over 28 years of experience in the pharmaceutical industry. He holds Masters degrees in both Chemistry and Statistics and a Doctorate of Sciences. As Senior Director at GSK, he leads the Quality by Design and Digital Platforms Group supporting small molecules, oligonucleotides, biopharmaceuticals, and vaccines CMC development. A pioneer in adapting QbD principles to analytical procedures, Phil has widely published in Analytical Chemistry. He has also served as Vice-Chair of the USP Measurement and Data Quality Expert Committee and Chair of the Joint Sub-Committee that developed general chapter &lt;1221&gt;.Presenter:&nbsp;Trish Meek (Sr Director, Connected Science, Waters Corporation)Trish Meek is a Sr. Director and Portfolio Owner in the Informatics Business Segment at Waters Corporation. In her current role, she leads the product management, development, cybersecurity and cloud infrastructure for Waters next generation cloud applications. Trish has over 25 years of experience in the laboratory informatics industry.Moderated by: Isabelle Vu Trieu (Pharmaceutical Market Development Manager, Americas, Waters Corporation)Isabelle is a business development professional dedicated to delivering benefits to analytical scientists in the life sciences industry. With over 20 years of experience in providing chromatography and mass spectrometry solutions, Isabelle is particularly interested in helping pharmaceutical scientists achieve the data quality and integrity needed to drive decisions for drug quality, safety and efficacy. Isabelle joined Waters in 2009 and currently manages the development of the pharmaceutical market in the Americas. She holds Masters’ degrees in Chemistry from Columbia University and the University Claude Bernard in Lyon, France as well as a Chemical Engineering degree from Ecole Supérieure de Chimie Physique Electronique in Lyon, France.</blockquote>

Ongoing Procedure Performance Verification

<div>At ASMS 2025, Bruker’s Life Science division unveiled a comprehensive range of cutting-edge products, including the timsUltra AIP, which boasts substantial enhancements in sensitivity redefining proteome analysis. This innovation can now be seamlessly integrated with the newly introduced proteoElute™ LC, featuring optimised nanoflow workflows that cater to high-throughput and ultra-sensitive multiomics experiments.Furthermore, the novel timsMetabo™ system was showcased, demonstrating improved sensitivity and accuracy in metabolomics research. Advanced software solutions, such as Proteoscape® 2026 and MetaboScape® 2026, were highlighted for their exceptional data analysis capabilities.Lastly, the groundbreaking timsOmni™ was unveiled, offering an eXtreme leap in deep proteoform sequencing and advanced structural elucidation using eXd fragmentation and MSn.<h5>Agenda</h5><ol><li>timsUltra AIP :Next generation ultra-sensitive instrument for cutting-edge research with uncompromised performance.</li><li>timsMetabo™ :Discovering MoRE in 4D-Metabolomics: Current challenges in small molecules analysis.</li><li>timsOmni ™ :Unlocking Deep Sequencing with timsOmni: The Future of Protein- and Nucleic Acid-Centric MS.</li><li>Updates on the Metaboscape, Omniscape and Proteoscape with new features and capabilities.</li><li>proteoElute™: ProteoElute UHPLC: A Flexible Solution for single-cell Proteomics.</li></ol></div>

Bruker: Latest Bruker MS Technologies from ASMS 2025

Latest Bruker MS Technologies from ASMS 2025

Explore Bruker’s latest mass spec innovations—timsUltra AIP, timsMetabo™, timsOmni™—and software tools driving ultra-sensitive multiomics and proteomics.

Join us for an enlightening webinar series designed to empower academicians and researchers by exploring the latest advancements and opportunities in pharmaceutical sciences. At Agilent, we recognize the unique challenges faced by academicians, researchers, and students. At PharmaFrontiers, we have curated a series of content tailored to address your needs and unlock new opportunities.The PharmaFrontiers seminar series is designed to provide you with valuable knowledge, insights, and practical skills.Topics to be covered:<ul><li>Introduction to Unlocking Intelligent Features of the Agilent Infinity III LC Series.&nbsp;</li><li>Advance your lab with the performance and intelligence of next-generation LC-MS detection.</li><li>Achieve More and Uncover Biological Insights Faster: End-to-End LC Platforms, LC/TQ, and LC/QTOF Workflows.</li></ul><blockquote>Presenter: Dr. Nirmal Thakker (Technical Application Support Specialist – Chromatography, Dissolution &amp; Lab Informatics, Agilent Technologies)Dr. Nirmal has done his PhD in quality assurance and pharmacy and his master's in pharmacy from the University of Pune. He has more than 15 years of overall industrial experience working in analytical research &amp; development for renowned multinational pharma companies like Glenmark, Torrent, and Piramal. He has also worked with Spinco Biotech as an application specialist for LC. Presently, he is working with Agilent Technologies as a technical application support specialist for chromatography, dissolution, and lab informatics. He has expertise in chromatography, QbD, method transfer, and mass spectrometry.Presenter: Vinayak AK (Pre-Sales Applications Engineer - LC/MS and Automation, Agilent Technologies)Vinayak AK began his career at Agilent in 2012 as a campus hire working as an application associate. He then transitioned to the segment marketing team as an application scientist, a role he held for 5 years. For the past 8 years, Vinayak has been serving as a pre-sales applications engineer/product specialist for LC and then for LC/MS. His expertise includes method development for MS-based impurity analysis and purification and cleaning validation workflows, utilizing solutions such as the Agilent 6150 Series Single Quadrupole LC/MS. Vinayak has published a total of 13 application notes across various workflow solutions based on Agilent UHPLC and QbD solutions, including 3 specifically on Agilent Single Quadrupole solutions.Presenter: Dr. Ashish Pargaonkar (Biopharma Market Development Specialist, Agilent Technologies)Dr. Ashish Pargaonkar is a Lead for Biopharma Workflow Commercialization team for India and also Manager for Centre of Excellences at Bangalore. A Microbiologist by education with a Ph.D, he holds more than 20 years of experience for Biopharma market applications on Hi Resolution Mass Spectrometry.He has a long record of successful demonstrations and customer engagements on workflows for CQA’s, Intact mass, peptide mapping, HCP and Glycans using Agilent state-of-the art solutions. He has authored ASMS posters on media components and therapeutic peptides. Dr. Ashish has been invited speaker at several conferences and workshops at Biosimilar Congress, ADC 2018, IIT (Mumbai, Delhi), ICT (Mumbai), PSI events.</blockquote>

Agilent Technologies: Pharma Frontiers Live Webinar Series: Analytical Techniques, Advances in Chromatography and Regulatory Compliance

Ensuring Excellence: Cutting-Edge Techniques for Pharmaceutical Analysis [LC/LCMS]

Discover smart LC features and next-gen LC-MS workflows. Learn how LC/TQ and LC/QTOF platforms can accelerate biological insights and lab productivity.

LC/LCMS Pharmaceutical Analysis

<h5>Overview</h5>During this presentation we will review:<ul><li>Advantages of the biphenyl LC column chemistry for drug analysis</li><li>Using phospholipid removal to produce cleaner samples and improve drug quantitation</li><li>Implementing mixed-mode SPE with in-well room temperature hydrolysis to extract “designer” benzodiazepines and conjugated metabolites from urine using a streamlined workflow</li><li>Strategies for removing endogenous constituents and collection device components from oral fluid samples prior to LC-MS/MS analysis using microelution SPE</li></ul><h5>Key Learning Points</h5><ul><li>Understand how LC column chemistry impacts LC-MS/MS drug analysis</li><li>Review how biological matrix components affect choices in sample extraction methods</li><li>Learn about streamlined extraction protocols for cleaner samples for LC-MS/MS analysis</li></ul><h5>Who Should Attend</h5><ul><li>Clinical and forensic toxicologists who want solutions to simplify and improve their LC-MS/MS drug analysis methods</li></ul><blockquote>Presenter: Stephanie J. Marin, Ph.D (Sr. Global Market Development Manager)Stephanie J. Marin is the Applied Markets Global Market Development Manager at Phenomenex. She received her Ph.D. in chemistry from Arizona State University, and has expertise in sample preparation, liquid chromatography and mass spectrometry. Dr Marin has worked in marketing, product development, method development and method validation, in addition to customer facing roles in technical support, service, education and training. She has over 10 years of experience developing and validating clinical methods from her tenure at the ARUP Institute for Clinical and Experimental Pathology. She has also held positions as an Applications Chemist at Hamilton Company and Biotage, Marketing Manager at Selerity Technologies and as a Group Leader in analytical services for specialty chemicals and polymers at Rohm and Haas (now Dow). She was also a supervisor at an EPA certified laboratory. She is the author of over 30 peer reviewed publications and book chapters and over 100 abstracts presented at national and international meetings.</blockquote>

Phenomenex: Simple Drug Testing Solutions for Complex Samples

Simple Drug Testing Solutions for Complex Samples

Explore SPE, biphenyl LC columns, and matrix cleanup strategies to streamline LC-MS/MS drug analysis in clinical and forensic toxicology.

LCMS webinars focusing on LC/MS | LabRulez LCMS